Published in Gene Therapy Weekly, March 11th, 2004
"VIR201 is the first treatment of its kind in the world to show an ability to block the progression of this potentially deadly virus in HIV positive patients," said Professor David Cooper, NCHECR director.
"On the clinical evidence now available, VIR201 is one of the most promising...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.